Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions
Poziotinib provides ‘modest but meaningful’ efficacy in NSCLC subgroup
Key clinical point: Poziotinib shrank tumors in a majority of patients with previously treated non–small cell lung cancer and EGFR exon 20 insertion mutations, but the response rate was low.
Major finding: Tumor shrinkage occurred in 65% of patients. About 15% achieved a response, and the median duration of response was 7.4 months.
Study details: A cohort of 115 patients in the ongoing phase 2 ZENITH20 study.
Disclosures: ZENITH20 is sponsored by Spectrum Pharmaceuticals Inc. Dr. Le disclosed relationships with Eli Lilly, AstraZeneca, EMD Serono, Boehringer Ingelheim, and Spectrum Pharmaceuticals.
Citation:
Le X et al. AACR 2020, Abstract CT081.